ライフサイエンスコーパス: drug-resistant tuberculosis

1 rammatically incurable tuberculosis (totally drug-resistant tuberculosis).

2 ti-drug resistant tuberculosis and extremely drug resistant tuberculosis.

3 alth Organization to treat leprosy and multi-drug-resistant tuberculosis.

4 resection is beneficial in the treatment of drug-resistant tuberculosis.

5 une-based therapies for adjunct treatment of drug-resistant tuberculosis.

6 s on the future burden of drug-sensitive and drug-resistant tuberculosis.

7 studies are warranted to define its role in drug-resistant tuberculosis.

8 le, we describe the current global status of drug-resistant tuberculosis.

9 of action in order to tackle the scourge of drug-resistant tuberculosis.

10 ting many cases of multidrug and extensively drug-resistant tuberculosis.

11 n and incidence of both drug-susceptible and drug-resistant tuberculosis.

12 gimen appeared to lead to the development of drug-resistant tuberculosis.

13 thrust for new drugs to counteract multiple drug-resistant tuberculosis.

14 ns-are likely crucial to the pathogenesis of drug-resistant tuberculosis.

15 is Commission, we examine several aspects of drug-resistant tuberculosis.

16 or, are being evaluated for the treatment of drug-resistant tuberculosis.

17 new therapeutic agents for the treatment of drug-resistant tuberculosis.

18 st distributions on the future prevalence of drug-resistant tuberculosis.

19 is study improves the chances of controlling drug-resistant tuberculosis.

20 tuation worldwide and the growing problem of drug-resistant tuberculosis.

21 and prevention of both drug-susceptible and drug-resistant tuberculosis.

22 treatment shortening of drug-susceptible and drug-resistant tuberculosis.

23 re a key determinant of the future burden of drug-resistant tuberculosis.

24 tidrug-resistant tuberculosis or extensively drug-resistant tuberculosis.

25 ates for multidrug-resistant and extensively drug-resistant tuberculosis.

26 s) severely compromises treatment options of drug-resistant tuberculosis.

27 ies is being explored for drug-sensitive and drug-resistant tuberculosis.

28 demic of multidrug-resistant and extensively drug-resistant tuberculosis.

29 of this structure class for the treatment of drug-resistant tuberculosis.

30 mmittee-supported programmatic management of drug-resistant tuberculosis.

31 eveloped as a therapy for drug-sensitive and drug-resistant tuberculosis.

32 potential therapeutic utility against highly drug-resistant tuberculosis.

33 osed a threat of transmission of extensively drug-resistant tuberculosis.

34 lish the efficacy of surgery in treatment of drug-resistant tuberculosis.

35 ude data on HIV/tuberculosis coinfection and drug-resistant tuberculosis.

36 resulted in a 40% increase in prevalence of drug-resistant tuberculosis after 20 years.

37 eatments for paediatric drug-susceptible and drug-resistant tuberculosis, albeit generally effective,

38 However, little is known about the rates of drug-resistant tuberculosis among health care workers in

39 together lead to high level resistance multi-drug resistant tuberculosis and extremely drug resistant

40 st multidrug-resistant (MDR) and extensively drug-resistant tuberculosis and an excellent pharmacolog

41 d isolates from 651 patients for extensively drug-resistant tuberculosis and developed regimens that

42 uences that are diagnostic of two pathogens (drug-resistant tuberculosis and Escherichia coli) by usi

43 ese advances are insufficient in the face of drug-resistant tuberculosis and HIV co-infection.

44 hical and medicolegal aspects of extensively drug-resistant tuberculosis and other resistant strains.

45 s a high-yield intervention for detection of drug-resistant tuberculosis and prevention of ongoing tr

46 The rise of multidrug-resistant and totally drug-resistant tuberculosis and the association with an

47 We describe the management of extensively drug-resistant tuberculosis and treatment outcomes among

48 eatment and management of drug-sensitive and drug-resistant tuberculosis, and provide an update on ne

49 c screens for bactericidal compounds against drug-resistant tuberculosis are beginning to yield novel

50 trials to optimize combinations of drugs for drug-resistant tuberculosis are lacking.

51 New approaches to the treatment of multi drug-resistant tuberculosis are needed.

52 tcomes with available treatment regimens for drug-resistant tuberculosis are poor.

53 ical, and genomic data from patient cases of drug-resistant tuberculosis backed by shareable, physica

54 so contribute substantially to the burden of drug-resistant tuberculosis because of their much higher

55 Extensively drug-resistant tuberculosis can be cured in HIV-negative

56 umber of multidrug resistant and extensively drug resistant tuberculosis cases continues to rise.

57 mplemented, and the actual numbers of global drug-resistant tuberculosis cases have yet to be estimat

58 The treatment of drug-resistant tuberculosis cases is challenging, as dru

59 To estimate the relative fitness of drug-resistant tuberculosis cases, we compared the incid

60 (HIV)-infected patients and the emergence of drug-resistant tuberculosis (DR-TB) is a growing problem

61 Increasingly complex drug-resistant tuberculosis (DR-TB) is a major global he

62 The management of children with drug-resistant tuberculosis (DR-TB) is challenging, and

63 atment of multidrug-resistant or extensively drug-resistant tuberculosis (DR-tuberculosis) is challen

64 ic activity, has the country response to the drug-resistant tuberculosis epidemic been so ineffectual

65 ere associated with more severe epidemics of drug-resistant tuberculosis, fitness distributions with

66 The patients with extensively drug-resistant tuberculosis had undergone more treatment

67 However, concern about drug-resistant tuberculosis has been eclipsed by that of

68 idrug-resistant tuberculosis and extensively drug-resistant tuberculosis has been noted, particularly

69 Extensively drug-resistant tuberculosis has been reported in 45 coun

70 ve improved with antiretroviral therapy, but drug-resistant tuberculosis has emerged as a major cause

71 The increasing prevalence of drug-resistant tuberculosis highlights the need for iden

72 en eclipsed by that of totally and extremely drug-resistant tuberculosis--ie, resistance to all or ne

73 tiative supported programmatic management of drug-resistant tuberculosis in 90 countries.

74 ining the transmissibility and prevalence of drug-resistant tuberculosis in a population were investi

75 s infections among patients at high risk for drug-resistant tuberculosis in Botswana.

76 osis in children; detection and treatment of drug-resistant tuberculosis in children; and a more effe

77 ould enable early detection and treatment of drug-resistant tuberculosis in clinical settings.

78 examine the relationship of HIV infection to drug-resistant tuberculosis in other selected regions of

79 y virus (HIV) coepidemic and rising rates of drug-resistant tuberculosis in parts of the world add fu

80 ribution of recent transmission to spread of drug-resistant tuberculosis in Texas, we performed IS611

81 o evidence for the extensive transmission of drug-resistant tuberculosis in Texas.

82 n informed approach to the classification of drug-resistant tuberculosis in the era of new drugs.

83 t, and outcomes of patients with extensively drug-resistant tuberculosis in Tomsk, Russia.

84 Factors associated with multi-drug-resistant tuberculosis included a history of previo

85 sonalized rather than empirical treatment of drug-resistant tuberculosis, including the use of antimi

86 infection was shown to be a risk factor for drug-resistant tuberculosis, independent of geographic l

87 ographical regions with a high prevalence of drug-resistant tuberculosis (India, Moldova, the Philipp

88 Extensively drug-resistant tuberculosis is a burgeoning global healt

89 s remains a major global health problem, and drug-resistant tuberculosis is a growing threat.

90 zinamide, the injectables, and isoniazid for drug-resistant tuberculosis is a high priority.

91 The emergence of drug-resistant tuberculosis is challenging tuberculosis

92 Treatment of drug-resistant tuberculosis is hindered by the high toxi

93 and duration of drugs with activity against drug-resistant tuberculosis is paramount.

94 anid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Le

95 etting where there is no ongoing outbreak of drug-resistant tuberculosis, isoniazid-resistant tubercu

96 for rapidly detecting multidrug-/extensively drug-resistant tuberculosis (M/XDR TB), but large studie

97 Emergence of drug-resistant tuberculosis makes the discovery of new t

98 s in these patients suggest that extensively drug-resistant tuberculosis may be acquired through prev

99 oor treatment outcomes associated with multi-drug resistant tuberculosis (MDR-TB) are of major concer

100 The emergence of multi- and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respecti

101 Multi-drug-resistant tuberculosis (MDR-TB) is an increasing pu

102 ncluding multidrug-resistant and extensively drug-resistant tuberculosis, might become less relevant.

103 Far more drug-resistant tuberculosis occurs in children than is d

104 273 South African patients with extensively drug-resistant tuberculosis, or resistance beyond extens

105 in the USA highlights the risks of acquiring drug-resistant tuberculosis overseas, and the unique cha

106 Household contact investigation around drug-resistant tuberculosis patients is a high-yield int

107 DR) tuberculosis, and more recently, totally drug-resistant tuberculosis pose a threat to global tube

108 resistant (MDR) tuberculosis and extensively drug-resistant tuberculosis poses a major threat to glob

109 Patients with extensively drug-resistant tuberculosis received daily, supervised t

110 tion-defined group 1, 2, and 4 drugs used in drug-resistant tuberculosis regimens to inform clinical

111 In some countries such as South Africa, drug-resistant tuberculosis represents less than 3% of a

112 data suggest that control of the epidemic of drug-resistant tuberculosis requires an increased focus

113 at interventions to prevent the emergence of drug-resistant tuberculosis should target bacterial as w

114 ield of such investigations in households of drug-resistant tuberculosis source cases is unknown.

115 uartile range, 21-302) household contacts of drug-resistant tuberculosis source cases.

116 s in 240 multidrug-resistant and extensively drug-resistant tuberculosis strains and quantified their

117 The resurgence of drug resistant tuberculosis (TB) is a significant global

118 Drug-resistant tuberculosis (TB) is emerging as a major

119 lity risk and improve treatment outcomes for drug-resistant tuberculosis (TB) patients, including ind

120 The increasing burden of drug-resistant tuberculosis (TB) poses an escalating thr

121 Drug-resistant tuberculosis (TB) presents a major challe

122 ing (DST) to design appropriate regimens for drug-resistant tuberculosis (TB).

123 uberculosis groups could affect epidemics of drug-resistant tuberculosis (TB).

124 in South Africa have undiagnosed active and drug-resistant tuberculosis (TB).

125 ontaining regimens are highly active against drug-resistant tuberculosis, the contribution of clofazi

126 1 patients tested, 48 (7.4%) had extensively drug-resistant tuberculosis; the remaining 603 patients

127 tted from 2003 to 2008 for the initiation of drug-resistant tuberculosis therapy.

128 Drug-resistant tuberculosis threatens recent gains in th

129 We non-randomly assigned 26 patients with drug-resistant tuberculosis to the DRMPa200Z regimen.

130 pril 1994, a passenger with infectious multi-drug resistant tuberculosis traveled on commercial-airli

131 ents with multidrug-resistant or extensively drug-resistant tuberculosis undergoing treatment is poor

132 None of the patients with extensively drug-resistant tuberculosis were coinfected with the hum

133 The largest number of cases of drug-resistant tuberculosis were reported in counties bo

134 berculosis, or resistance beyond extensively drug-resistant tuberculosis, were followed up over a per

135 nts with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often lim

136 erculosis treatment and manage patients with drug-resistant tuberculosis who are infected with HIV ar

137 Retrospective study of patients with drug-resistant tuberculosis who were admitted from 2003

138 gnosis of 20 downstream cases of extensively drug-resistant tuberculosis with almost identical sequen

139 We undertook enhanced surveillance for drug-resistant tuberculosis with sputum culture and drug

140 ogists from countries with a heavy burden of drug-resistant tuberculosis working with data scientists

141 SLDs) is a problem in treating patients with drug-resistant tuberculosis worldwide.

142 istant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) (M/XDR-TB).

143 ansmission has been described in extensively drug-resistant tuberculosis (XDR-TB) and HIV co-infected

144 Worldwide emergence of extensively drug-resistant tuberculosis (XDR-TB) has raised global p

145 culosis (Mtb) have given rise to extensively drug-resistant tuberculosis (XDR-TB).

146 Extensively drug-resistant tuberculosis (XDR-tuberculosis) is a glob